Drug
Avasopasem manganese clinical trials
Also written GC4419.
How studies write it
Studies that test it under each name
Name
Development codes
Studies by the year they started
13 studies that test it; most in 2017 (3)
| Year | Studies |
|---|---|
| 2013 | 1 |
| 2015 | 1 |
| 2017 | 3 |
| 2018 | 3 |
| 2019 | 3 |
| 2020 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 13 · Other 0
Galera Therapeutics, Inc. (13)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses avasopasem manganese is read from its arms, and is right about nine times in ten.
Testing it · 13
- Pilot Dose Escalation Trial of Stereotactic Body Radiation Therapy (SBRT) in Combination With GC4419 in Pancreatic CancerCompletedPhase 1/2Galera Therapeutics, Inc.NCT03340974Written as GC4419
- ROMAN: Phase 3 Trial Investigating the Effects of GC4419 on Radiation Induced Oral Mucositis in Head/Neck Cancer PatientsCompletedPhase 3Galera Therapeutics, Inc.NCT03689712Written as GC4419 90mg
- Effects of Intravenous GC4419 on the Incidence and Severity of Esophagitis Due to Chemoradiotherapy for Lung CancerTerminatedPhase 2Galera Therapeutics, Inc.NCT04225026Written as GC4419 (avasopasem manganese)
- Ph 2 Open Label Study of GC4419 to Reduce SOM Associated With Chemoradiotherapy for Head and Neck CancerCompletedPhase 2Galera Therapeutics, Inc.NCT04529850Written as Drug: GC4419
- Study to Evaluate the Effects of Renal Impairment on the Pharmacokinetics, Safety and Tolerability of GC4419CompletedPhase 1Galera Therapeutics, Inc.NCT05412472Written as GC4419
- A Trial of GC4419 in Patients With Critical Illness Due to COVID-19TerminatedPhase 2Galera Therapeutics, Inc.NCT04555096Written as GC4419
- A Study of the Effects of GC4419 on Radiation Induced Oral Mucositis in Patients With Head/Neck CancerCompletedPhase 2Galera Therapeutics, Inc.NCT02508389Written as Low Dose GC4419: 30mg/day
- A Phase 1 Study of the Safety and Pharmacokinetics of GC4711 (Oral Capsule) Compared to GC4419 (IV Infusion) and GC4711 (IV Infusion) in Healthy VolunteersCompletedPhase 1Galera Therapeutics, Inc.NCT03099824Written as IV GC4419
- Study to Evaluate the Effects of 90 mg Intravenous Infusions of GC4419 on the Single Dose Pharmacokinetics of Dextromethorphan in Healthy Adult SubjectsCompletedPhase 1Galera Therapeutics, Inc.NCT03792971Written as GC4419
- A Study Designed to Compare the Safety and Pharmacokinetics of Intravenously Administered Superoxide Dismutase Mimetic GC4711 and GC4419 in Healthy VolunteersCompletedPhase 1Galera Therapeutics, Inc.NCT03194139Written as GC4419 45 mg IV
- A Study to Investigate the Absorption, Metabolism, Excretion, and Mass Balance of GC4419 in Healthy Adult SubjectsCompletedPhase 1Galera Therapeutics, Inc.NCT03163173Written as GC4419
- A Phase 1, Randomized, Placebo-and Positive-Controlled Crossover Study to Determine the Effect of Single-Dose GC4419 on QTc Interval in Healthy VolunteersCompletedPhase 1Galera Therapeutics, Inc.NCT03164109Written as GC4419 IV
- A Phase 1 Dose Escalation Study of GC4419 in Combination With Chemoradiation for Squamous Cell Cancer of the Head & NeckCompletedPhase 1Galera Therapeutics, Inc.NCT01921426Written as GC4419
Codes
What other systems call avasopasem manganese · ClinicalTrials.gg INT001335
- MeSH (NLM) C000707700avasopasem manganeseConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) EY1WA413ULAVASOPASEM MANGANESEConfirmed FDA, NLM
- NCI Thesaurus C169797Avasopasem ManganeseOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000707700 | avasopasem manganese | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | EY1WA413UL | AVASOPASEM MANGANESE | Confirmed FDA, NLM |
| NCI Thesaurus | C169797 | Avasopasem Manganese | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.